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IMPORTANCE Comprehensive understanding of the genomic and gene-expression
differences between retinoblastoma tumors from patients with bilateral disease may help
to characterize risk and optimize treatment according to individual tumor characteristics.
OBJECTIVE To compare the genomic features between each eye and a specimen from
an orbital relapse in patients with bilateral retinoblastoma.
DESIGN, SETTING, AND PARTICIPANTS In this case, 2 patients with retinoblastoma underwent
upfront bilateral enucleation. Tumor samples were subjected to genomic and
gene-expression analysis. Primary cell cultures were established from both of the tumors
of 1 patient and were used for gene-expression studies.
MAIN OUTCOMES AND MEASURES Whole-exome sequencing was performed on an Illumina
platform for fresh tumor samples and DNA arrays (CytoScan or OncoScan) were used for
paraffin-embedded samples and cell lines. Gene-expression analysis was performed using
Agilent microarrays. Germinal and somatic alterations, copy number alterations, and
differential gene expression were assessed.
RESULTS After initial bilateral enucleation, patient 1 showed massive choroidal and laminar
optic nerve infiltration, while patient 2 showed choroidal and laminar optic nerve invasion.
Patient 1 developed left-eye orbital recurrence and bone marrow metastasis less than 1 year
after enucleation. Both ocular tumors showed gains on 1q and 6p but presented other distinct
genomic alterations, including an additional gain in 2p harboring the N-myc proto-oncogene
(MYCN) in the left tumor and orbital recurrence. Similar copy number alterations between
the orbital recurrence and the left eye supported the origin of the relapse, with an additional
11q loss only detected in the orbital relapse. Specimens from patient 2 showed common
copy number gains and losses, but further evolution rendered a 2p gain spanning MYCN in
the left tumor. For this patient, microarray expression analysis showed differential expression
of the MYCN and the forkhead box protein G1 (FOXG1) gene pathways between the left and
right tumors.
CONCLUSIONS AND RELEVANCE Differential genomic and gene expression features were
observed between tumors in 2 patients with bilateral disease, confirming intereye
heterogeneity that might be considered if targeted therapies are used in such patients.
Chromosomal alteration profile supported the origin of the orbital recurrence from the
homolateral eye in 1 patient. Loss in chromosome 11q may have been associated with
extraocular relapse in this patient.
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B ilateral retinoblastoma usually presents with asym-metric tumors, with 1 eye showing more advanced dis-ease than the fellow eye, suggesting that despite hav-
ing a common germinal RB1 mutation, other factors may play
a role in tumor genesis and progression.1,2 If the tumor is not
diagnosed timely, it may progress in both eyes to advanced dis-
ease requiring bilateral enucleation. Upfront bilateral enucle-
ation is seldom performed in high-income countries; thus,
when performed, it gives the opportunity of evaluating ge-
nomic and gene expression differences that might be present
between eyes without the effect of any therapy that could cause
clonal selection.3,4 Herein, we analyzed the genomic and gene
expression features between tumors in 2 cases of initially
enucleated bilateral retinoblastoma.
Methods
The study was approved by Hospital de Pediatría J.P. Garrahan
institutional review board. Written informed consent was ob-
tained from parents or guardians of patients, and all proce-
dures involving human participants were in accordance with the
ethical standards and the Declaration of Helsinki. No compen-
sation or incentive was provided to participants of the study.
Patients
Patient 1 and patient 2 had bilateral Group E retinoblastoma
(Figure 1) with no evidence of extraocular extension. Patient 1
underwent upfront bilateral enucleation. Histopathological as-
sessments of both eyes showed massive choroidal invasion and
laminar optic nerve involvement. The patient did not receive
adjuvant therapy, and after less than a year, a left-orbital and
bone marrow relapse occurred. The patient was treated with sys-
temic chemotherapy and died of disease progression.
In patient 2, histopathological evaluations showed the right
eye with massive choroidal, intrascleral, and postlaminar optic
nerve involvement, while the left eye had focal choroidal and
prelaminar optic nerve tumor extension. The patient received
adjuvant chemotherapy5 and remains alive and disease free.
Genomic Studies and Gene Expression Analysis
Genome studies for copy number alterations (CNA) and loss-
of-heterozygosity analysis were performed with OncoScan CNV
Assay (Thermo Fisher) or SureSelect Clinical Research Exome
version 2 (Agilent Technologies), followed by sequencing on
an Illumina HiSeq 4000 instrument (Illumina Inc), depend-
ing on the availability of fresh or formalin-fixed, paraffin-
embedded samples. The analysis of CNAs and somatic and
germline variants was performed as described in the eMethods
in the Supplement. Two-color, microarray-based gene-
expression analysis was performed according to manufactur-
er’s recommendations (eMethods in the Supplement). Data
were collected from August 2016 to October 2017.
Patient-Derived Cell Cultures
Low-passage retinoblastoma cell cultures were obtained from
fresh samples6 from both eyes of patient 2 and named HPG-
RBT-12L and HPG-RBT-12R. A CytoScan HD Assay (Thermo
Fisher) was used for CNA analysis of both cell cultures and com-
pared with the genomic profiles of the matched tumors for
qualitative similarities in the presence or absence of segment
gains and losses (eMethods in the Supplement).
Data Analysis
Data were analyzed from November 2017 to January 2019. A de-
tailed description is in the eMethods in the Supplement. Briefly,
genomic variant analysis from whole exome sequencing
was performed by IntegraGen according to their pipeline
(http://www.integragen-genomics.com/bioinformatics-and-
bioanalysis) and manual review was done with Alamut Visual
version 2.10 (Interactive Biosoftware). Copy number alterations
were evaluated by reprocessing sequencing files with the
Burrows-Wheeler Aligner for alignment, Sambamba for
duplicates removal, and the Genome Alteration Print method
for ploidy and copy number profiles. The CNA analysis for DNA
array files was performed with Chromosome Analysis Software
(Thermo Fisher). Final processing in both cases was done
in R/Bioconductor version 3.5 (R Project for Statistical
Computing). Expression data analysis was performed in
R/Bioconductor version 3.5 (R Project for Statistical Computing),
the InnateDB database, Pathway Recognition Algorithm
using Data Integration on Genomic Models (PARADIGM), and
MultiExperiment Viewer software MeV version 4.9 (MEV).
Significance for differentially expressed genes was set at
P < .001 and fold change at 2 or greater.
Results
Genomic differences between eyes were present in patient 1,
while the orbital relapse resembled the homolateral eye. Pa-
tient 1 showed a previously reported germline heterozygous
deletion of the retinoblastoma protein (RB1) gene (Leiden Open
Variation Database; RB1_00509). A CNA analysis showed that
only gains at chromosomes 1q and 6p were present in both ocu-
lar tumors, despite differences in the absolute copy numbers.
Chromosome 13q showed a normal copy number in the right
tumor, while in the left tumor it was in loss of heterozygosity,
Key Points
Question Do both ocular tumors of patients with bilateral
retinoblastoma show similar genomic and gene expression
features?
Findings In this case report, 2 patients with bilateral
retinoblastoma showed eye tumors with distinctive genomic
profiles; chromosomal alteration profile supported the origin of
the orbital recurrence from the homolateral eye in 1 patient, and
in this case, 11q loss may be associated with extraocular relapse.
Transcription factor pathways were differentially expressed
between the left-eye and right-eye tumors in the second patient.
Meaning These 2 cases suggest genomic and gene expression
differences between tumors in patients with bilateral disease and
confirm intereye tumor heterogeneity that might be considered
with targeted therapies.
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with a concomitant gain of the mutated allele. The second hit
could not be identified for the right-eye tumor. Additionally,
a gain in 20q and a deletion of chromosome 16 were present
exclusively in the right eye, while the left tumor showed ad-
ditional gains in 2p (harboring the N-myc proto-oncogene
[MYCN]), 15q, and 22q11.1, and a loss in 9p21 (Figure 2A and
B; eTable 1 in the Supplement). Tumor from the left orbital re-
currence showed CNAs that closely resembled those found in
the left intraocular tumor but showed an additional 11q loss
and difference in the absolute copy number of 6p (Figure 2C).
The ocular tumors of patient 2 also showed genomic dif-
ferences. For patient 2, a germline and heterozygous muta-
tion in RB1 c.1421G>T (p.(Ser474Ile)) was detected. Among the
somatic alterations (eTable 2 in the Supplement), a patho-
genic mutation in the BCL6 corepressor (BCOR) gene in an
allele frequency of 6% was identified only in the left tumor
(ClinVar; RCV000538294.1).
Both intraocular tumors showed similar CNA profiles shar-
ing gains in 1q, 6p, and 14q11.2, a 13q loss that includes RB1 in loss
of heterozygosity (considered the second hit), and a subclonal
loss at 8p23 (Figure 3A and B). Differences included a focal clonal
gain of MYCN as part of a subclonal gain in 2p, exclusively found
in the left tumor, and the allelic ratio in 6p gain. Deletions in 13q
showed different boundaries between eyes, and the telomeric
end of the right tumor was in copy-neutral loss of heterozygos-
ity. Altogether, in addition to RB1 alterations, proposed by Alfred
G. Knudson, Jr, MD,2 and required for retinoblastoma initiation,
additional genetic changes are summarized in eTable 3 in the
Supplement, and a hypothesis for tumor evolution in both pa-
tients is depicted in eFigure 1 in the Supplement.
Primary cell cultures derived from patient 2 resembled the
genetic features of the matched-ocular tumors. Similar CNAs
to the ocular tumors were detected for the matched-cell mod-
els (Figure 3C and D; eTable 4 in the Supplement). Observed
differences may correspond to changes in clonality (ie, a sub-
clonal gain of 2p only in the left tumor that became clonal in
HPG-RBT-12L cells). Unsupervised hierarchical clustering of
the whole-gene expression data set showed that cell lines
grouped together with their corresponding tumor of origin
(eFigure 2 in the Supplement). The comparisons of right vs left
tumors and HPG-RBT-12R cells vs HPG-RBT-12L cells showed
997 and 1186 differentially expressed genes (DEGs; P < .001;
eFigure 2 in the Supplement) while tumor vs matching cell line
comparison resulted in almost no DEGs (eFigure 2 in the
Supplement). Gene ontology enrichment analysis performed
with the common DEGs upregulated in the left tumor and
HPG-RBT-12Lcells (eFigure 2 in the Supplement) rendered the
term DNA-binding transcription factors to indicate the most
significantly enriched element. Specifically, MYCN was sig-
nificantly upregulated in both specimens. A hierarchical clus-
Figure 1. Images at Presentation
Patient 1 right eyeA Patient 1 left eyeB
Patient 2 right eyeC Patient 2 left eyeD
A and B, Patient 1’s right and left eyes
at presentation. C and D, Clinical
presentation of the right and left eyes
of patient 2.
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tering using genes from 2 previously reported MYCN gene
signatures7,8 resulted in the correct segregation of the right and
left tumors and cell lines (eFigure 3 in the Supplement).
The FOXG1 gene was the most pronounced DEG between the
left-eye and right-eye tumors and the derived cell lines (eFigure 2
in the Supplement). A hierarchical clustering performed with a
previously reported FOXG1 gene signature revealed 2 distinct
clusters of right vs left specimens (eFigure 3 in the Supplement).9
Both analyses suggested an influence of MYCN and FOXG1 in
the differential phenotype of the left tumor of patient 2.
Discussion
Comparative tumor biology studies between eyes simultane-
ously enucleated at diagnosis in bilateral retinoblastoma have
not been reported thus far. We found differences in genomic
aberrations and gene-expression profiles, suggesting tumor
heterogeneity in 2 patients with initial bilateral enucleation.
Intertumor heterogeneity, including gains in MYCN, may
be determinants for the evolution of more aggressive tumors
as shown in both patients studied. Also, intratumor heteroge-
neity is suspected by the finding that 6% of the left-eye
tumor cells of patient 2 presented a mutation in BCOR.2,4
Copy number alteration analysis indicated that the ori-
gin of the orbital relapse in patient 1 was the homolateral
eye. A deletion in 11q was found in the orbital tissue, a
known risk factor for neuroblastoma that has also been
reported in few intraocular retinoblastomas but not associ-
ated with an increased risk of extraocular relapse.10-13 More-
over, patient 1 showed a MYCN gain in both the left eye and
orbital relapse, but this was absent in the right eye. The
MYCN gene is a known driver in solid pediatric tumors, and
its amplification has been proposed as a driver of retinoblas-
toma in cases with wild-type RB111,14; however, MYCN gains
have also been reported in 65% of initially enucleated eyes
of patients who are RB−/−, and its prognostic implications are
not clear.11
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A, Right-eye tumor. B, Left-eye tumor. C, Orbital recurrence. Each dot
represents a log ratio of tumor signal compared with the normal reference.
Losses and gains in chromosomal regions correspond with negative and
positive values, respectively. The y-axis depicts the log ratio, and chromosomal
positions are represented in the x-axis (Chr indicates chromosome). The orbital
recurrence shows a similar profile to the left eye, with an additional loss at 11q.
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In addition to a differential gene expression profile
of the MYCN pathway between eye tumors in patient 2,
we also report an upregulated gene expression of FOXG1
pathway in the absence of a copy number gain of this
gene. The FOXG1 gene is involved in telencephalon develop-
ment, and it has been proposed to play a role in glio-
blastoma and medulloblastoma, despite no reports in
retinoblastoma.9,15
Limitations
The limitation of this series is its small sample size. Our findings
cannot be generalized until they are confirmed in larger studies.
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A, Right-eye tumors. B, Left-eye tumors. C and D, Matched primary cell lines.
Similar chromosomal alterations were detected between eye tumors, except
for a 2p gain encompassing the MYCN gene locus. The chromosomal profiles
of both HPG-RBT-12R (C) and HPG-RBT-12L (D) cells were similar to the
matched original tumors, with no additional alterations. Chr indicates
chromosome.
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Conclusions
The present study shows intereye and intratumor heterogeneity
in 2 patients with simultaneously enucleated bilateral retino-
blastoma and suggests each affected eye might be considered
individually for potential targeted therapies based on specific
genetic and differential gene expression features. In 1 patient,
the orbital relapse showed an 11q loss absent in the homolateral
eye that could be associated with extraocular relapse.
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